Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Frontiers in Oncology|November 15, 2021
Spatial Distribution of Immune Cells in Head and Neck Squamous Cell CarcinomasChristian Idel, Julika Ribbat-Idel, Luise Klapper, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 22, 2019
A randomized trial (RAREST-01) comparing Mepitel® Film and standard care for prevention of radiation dermatitis in patients irradiated for locally advanced squamous cell carcinoma of the head-and-neck (SCCHN)Dirk Rades, Carlos A Narvaez, Laura Splettstößer, et al.
International Journal of Molecular Sciences|March 29, 2023
TRIM21 Expression as a Prognostic Biomarker for Progression-Free Survival in HNSCCAmelie von Bernuth, Julika Ribbat-Idel, Luise Klapper, et al.
BMC Cancer|April 12, 2024
Partial recovery of peripheral blood monocyte subsets in head and neck squamous cell carcinoma patients upon radio(chemo)therapy is associated with decreased plasma CXCL11Christian Idel, Jonas Fleckner, Kirstin Plötze-Martin, et al.
Frontiers in Oncology|January 28, 2026
HIF-2α accumulation in human monocytes upon transfer of hypoxia-associated miRNAs via plasma-derived small extracellular vesicles from head and neck cancer patientsMarie-Nicole Theodoraki, Linda Hofmann, Helen Bauer, et al.
BMC Cancer|September 20, 2024
Type 2-like polarization and elevated CXCL4 secretion of monocyte derived macrophages upon internalization of plasma-derived exosomes from head and neck cancer patientsMarie-Nicole Theodoraki, Diana Huber, Linda Hofmann, et al.
Cancer Medicine|September 14, 2023
Demographics and access to head and neck cancer care in rural areas compared to urban areas in GermanyJulius M Vahl, Gabriele Nagel, Ayla Grages, et al.
The American Journal of Pathology|November 7, 2017
Immunometabolic Determinants of Chemoradiotherapy Response and Survival in Head and Neck Squamous Cell CarcinomaRosemarie Krupar, Matthias G Hautmann, Ravi R Pathak, et al.
Cancer Immunology Research|January 24, 2014
Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancerDavid C Binder, Boris Engels, Ainhoa Arina, et al.
Frontiers in Medicine|May 14, 2021
Performance of Different Diagnostic PD-L1 Clones in Head and Neck Squamous Cell CarcinomaJulika Ribbat-Idel, Franz F Dressler, Rosemarie Krupar, et al.
Pageof 6